Annual report pursuant to Section 13 and 15(d)

Collaborative, Licensing and Other Arrangements - Novartis - Additional Information (Details)

v3.6.0.2
Collaborative, Licensing and Other Arrangements - Novartis - Additional Information (Details)
 1 Months Ended 3 Months Ended 12 Months Ended
Dec. 31, 2016
USD ($)
Nov. 30, 2008
USD ($)
Product
Dec. 31, 2015
USD ($)
Dec. 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
Dec. 31, 2014
USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
License and collaborative fees       $ 3,296,000 $ 49,064,000 $ 5,683,000
Novartis [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Upfront payment received     $ 37,000,000      
Performance deliverable period for license and regulatory services         90 days  
Performance deliverable period for transfer of materials, process and knowhow         90 days  
Performance deliverables value on stand alone basis         $ 0  
Novartis [Member] | Development Milestone [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Future milestone payments, maximum   $ 14,000,000        
Collaborative Arrangement [Member] | Novartis [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Royalty right expiration period   20 years        
Milestone received under the collaboration agreement $ 0          
License and collaborative fees       0 0 $ 0
Maximum borrowing capacity under loan agreement $ 50,000,000     $ 50,000,000    
Research and development expenses funded through loan facility, maximum (in hundredths)       75.00%    
Upfront payment received         $ 37,000,000  
Eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones       $ 480,000,000    
Collaborative Arrangement [Member] | Novartis [Member] | Development Milestone [Member]            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Number of ongoing product programs with potential royalty right milestone payments | Product   2